Publications
Publications
Show Results For
- All HBS Web
(4,600)
- Faculty Publications (806)
Returns
→
- August 2001
- Case
Strategic Capital Management, LLC (C)
By: Mark L. Mitchell, Erik Stafford and Todd Pulvino
Supplements the (A) case. View Details
- June 2001 (Revised November 2004)
- Case
Kingsley Management
Includes a brief overview of key challenges facing recent HBS graduates seeking funding for a business, followed by a 22-page excerpt from the Kingsley Management business plan. Describes Matthew Lieb and Chris Jones, two of the partners who developed the business plan... View Details
- February 2001 (Revised October 2006)
- Case
McDuffy, Arms & Ginsberg
By: Jay W. Lorsch
Describes the musings of the managing partner of a law firm as he returns from an executive education program. He thinks about the many issues confronting him and his firm. Teaching Purpose: To prepare executive education participants to return to their companies and... View Details
- February 2001
- Article
The Portfolio Flows of International Investors
By: K. A. Froot, P. O'Connell and M. Seasholes
- January 2001 (Revised March 2002)
- Case
Ford Motor Company's Value Enhancement Plan
By: Andre F. Perold
In April 2000, Ford Motor Co. announced a shareholder Value Enhancement Plan (VEP) to significantly recapitalize the firm's ownership structure. Ford had accumulated $23 billion in cash reserves and under the VEP would return as much as $10 billion of this cash to... View Details
- January 2001 (Revised May 2001)
- Case
Return Logic, Inc. (A)
By: Richard G. Hamermesh and Michele Lutz
Follows three graduating HBS students as they build a business-to-business Internet venture and highlights the challenges they confront in structuring financing terms with venture capitalists. Requires students to carefully read a six-page term sheet to identify which... View Details
- January 2001 (Revised May 2001)
- Teaching Note
Return Logic, Inc. (A) and (B) TN
By: Richard G. Hamermesh and Michele Lutz
Teaching Note for (9-801-167) and (9-801-168). View Details
- January 2001 (Revised May 2001)
- Case
Return Logic, Inc. (B)
By: Richard G. Hamermesh and Michele Lutz
Highlights how multiple rounds of financing work in practice and illustrates how terms agreed to in early-stage financing deals have an impact in later financing rounds. Also illustrates ethical issues that entrepreneurs confront as they build "dot-com" ventures. View Details
- January 2001
- Case
Valuing Project Achieve
By: Mihir A. Desai and Kathleen Luchs
Project Achieve is a start-up providing information management solutions for schools. Its founders see a need for software both to manage the volumes of information necessary to administer a school and to connect parents, teachers, and students in a more effective way.... View Details
- 2001
- Chapter
Publicly Funded Science and the Productivity of the Pharmaceutical Industry
By: Rebecca Henderson and Ian Cockburn
U.S. taxpayers funded $14.8 billion of health related research last year, four times the amount that was spent in 1970 in real terms. In this paper we evaluate the impact of these huge expenditures on the technological performance of the pharmaceutical industry. While... View Details
- December 2000 (Revised May 2001)
- Supplement
State of South Carolina
Spreadsheet to (9-201-061). Presents exhibits 1 and 2. Download only. View Details
- November 2000 (Revised July 2019)
- Teaching Note
Cafes Monte Bianco: Building a Profit Plan
By: Robert Simons and Indra Reinbergs
Teaching Note for (9-198-088). View Details
- November 2000 (Revised May 2001)
- Case
State of South Carolina, The
This case presents the managerial dilemma faced by the treasurer of South Carolina in 1998. Until last year, the South Carolina state pension fund (with over $17 billion in assets) was barred by the state constitution from investing in equities. After the constitution... View Details
- October 2000
- Article
The Equity Share in New Issues and Aggregate Stock Returns
By: Malcolm Baker and Jeffrey Wurgler
The share of equity issues in total new equity and debt issues is a strong predictor of U.S. stock market returns between 1928 and 1997. In particular, firms issue more equity than debt just before periods of low market returns. The equity share in new issues has... View Details
- August 2000 (Revised July 2002)
- Background Note
Fundamental Enterprise Valuation: Introduction
The purpose of this series of notes is to define the key "drivers" of the fundamental value of equity and to illustrate how these drivers determine the future cash flows and the "present value pattern" of the underlying common stock. The series includes one technical... View Details
- August 2000 (Revised July 2002)
- Background Note
Fundamental Enterprise Valuation: Return on Invested Capital (ROIC)
A technical note that defines return on invested capital (ROIC). View Details
- August 2000 (Revised July 2002)
- Background Note
Fundamental Enterprise Valuation: Short- and Long-Term Growth Rates and the Growth Horizon
A technical note that defines short- and long-term growth rates and the growth horizon. View Details
- July 2000 (Revised November 2001)
- Case
Catalyst Medical Solutions
By: Amy C. Edmondson, Richard M.J. Bohmer and Naomi Atkins
Faced with a drop in the NASDAQ, four eHealth entrepreneurs must decide between two distribution strategies for their new company's technology. The team, comprised of three full-time resident physicians and an MBA, has developed software to enable electronic... View Details
- 2000
- Other Unpublished Work
Career Concerns and Staged Investment: Evidence from the Venture Capital Industry
By: Malcolm Baker
I develop a model in which career concerns lead to inefficient reinvestment decisions. Managers have incentives to inflate interim returns by continuing bad projects and delaying write-offs. In the venture capital industry, the syndication of follow-on investments can... View Details
- May 2000
- Case
To Trim or Not to Trim: That Is the Question
By: Srikant M. Datar
Should Novartis drop 20% of its global pharmaceutical product brands that account for only 3% of its pharmaceutical revenues? View Details